Jones E W, Hawkey C J
Prostaglandins Leukot Med. 1983 Sep;12(1):67-71. doi: 10.1016/0262-1746(83)90068-9.
The balance between thromboxane A2 (a vasoconstrictor) and prostacyclin (a vasodilator) may be important in the pathogenesis of Raynaud's phenomenon. Dazoxiben is a selective inhibitor of thromboxane synthetase, with no effect on prostacyclin synthetase. It has been shown to abolish cold induced forearm vasoconstriction in normal volunteers. We have compared its effect with that of placebo in a double blind crossover study in eight patients with severe Raynaud's phenomenon. No consistently clinically useful benefit was demonstrated from three weeks' treatment with dazoxiben, and there were no significant changes in finger temperature or finger blood flow. We conclude that dazoxiben at this dosage is unlikely to be of practical clinical benefit in Raynaud's phenomenon.
血栓素A2（一种血管收缩剂）和前列环素（一种血管扩张剂）之间的平衡在雷诺现象的发病机制中可能很重要。达唑氧苯是血栓素合成酶的选择性抑制剂，对前列环素合成酶无作用。已证明它能消除正常志愿者冷诱导的前臂血管收缩。我们在一项双盲交叉研究中，将八名严重雷诺现象患者使用达唑氧苯的效果与安慰剂进行了比较。达唑氧苯治疗三周未显示出持续的临床有用益处，手指温度或手指血流量也无显著变化。我们得出结论，这种剂量的达唑氧苯在雷诺现象中不太可能具有实际临床益处。
